U.S. market Open. Closes in 3 hours 34 minutes

ATRC | AtriCure, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 35.76 - 37.04
52 Week Range 18.94 - 39.05
Beta 1.37
Implied Volatility 97.41%
IV Rank 34.73%
Day's Volume 152,920
Average Volume 567,101
Shares Outstanding 48,753,300
Market Cap 1,773,645,054
Sector Healthcare
Industry Medical - Instruments & Supplies
IPO Date 2005-08-05
Valuation
Profitability
Growth
Health
P/E Ratio -43.83
Forward P/E Ratio N/A
EPS -0.83
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 1,200
Country USA
Website ATRC
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
*Chart delayed
Analyzing fundamentals for ATRC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is strong. For more detailed analysis please see ATRC Fundamentals page.

Watching at ATRC technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ATRC Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙